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6-Gingerol, a natural component of ginger, has been widely reported to possess antiinﬂammatory and antitumorigenic activities.
Despite its potential eﬃcacy against cancer, the anti-tumor mechanisms of 6-gingerol are complicated and remain sketchy. In
the present study, we aimed to investigate the anti-tumor eﬀects of 6-gingerol on colon cancer cells. Our results revealed that 6-
gingerol treatment signiﬁcantly reduced the cell viability of human colon cancer cell, LoVo, in a dose-dependent manner. Further
ﬂow cytometric analysis showed that 6-gingerol induced signiﬁcant G2/M phase arrest and had slight inﬂuence on sub-G1 phase
in LoVo cells. Therefore, levels of cyclins, cyclin-dependent kinases (CDKs), and their regulatory proteins involved in S-G2/M
transition were investigated. Our ﬁndings revealed that levels of cyclin A, cyclin B1, and CDK1 were diminished; in contrast,
levels of the negative cell cycle regulators p27Kip1 and p21Cip1 were increased in response to 6-gingerol treatment. In addition, 6-
gingerol treatment elevated intracellular reactive oxygen species (ROS) and phosphorylation level of p53. These ﬁndings indicate
that exposure of 6-gingerol may induce intracellular ROS and upregulate p53, p27Kip1, and p21Cip1 levels leading to consequent
decrease of CDK1, cyclin A, and cyclin B1 as result of cell cycle arrest in LoVo cells. It would be suggested that 6-gingerol should
be beneﬁcial to treatment of colon cancer.
1.Introduction
Colorectal cancer (CRC) is one of the most prevalent can-
cers with high mortality in the western world and Taiwan
[1]. CRC is inclined to evolve into invasive cancer from
adenomatous polyps through mutations in various genes
[2]. Although early diagnosis improves patients’ clinical out-
comes, 5-year survival rate of patients diagnosed with CRC
is poor. Current therapeutic regimens for CRC constitute
predominantly of surgical procedures and chemotherapy [3,
4]. Despite improvements in the prognosis of CRC patients
receiving appropriate clinical modularity, resistance to
advancedtherapydoesoccurinmanypatientssuﬀeringfrom
incomplete eradication of malignant cells and metastasis.
Of various phytochemicals showing various biochemical
and pharmacologic activities, 6-gingerol, a major pharma-
cologically active component of ginger, has been reported
to exhibit antioxidant and anti-inﬂammatory properties and
exert substantial anticarcinogenic and antimutagenic activit-
ies [5]. Mounting evidence suggests that 6-gingerol is eﬀec-
tive in suppressing the transformation, hyperproliferation,
and inﬂammatory processes that initiate and promote car-
cinogenesis,aswellasthelaterstepsofcarcinogenesis,name-
ly, angiogenesis and metastasis [6–10]. Despite awareness to
its activity against several human cancers, the exact mol-
ecular mechanism underlying anti-tumoral eﬀects of 6-gin-
gerol remains sketchy.
Accumulating evidence suggests that induction of reac-
tive oxygen species (ROS) by phytochemicals are critically
involved in their anti-tumoral activity [11, 12]. Increase of
intracellular ROS usually leads to DNA damage, and the
subsequent phosphorylation of p53 contributes to cell cycle
arrest and further apoptosis of cancer cell. The role of cell2 Evidence-Based Complementary and Alternative Medicine
cycle mediators in cancer development is now well docu-
mented. Critical genes responsible for cell cycle regulation as
checkpoints have been demonstrated to be lost and/or aber-
rant in a variety of cancers in human [13]. Cell cycle is under
sophisticated regulation through the interactions of diﬀerent
cyclins with their speciﬁc kinases, cyclin-dependent kinases
(CDKs) [14]. Two classes of CDK inhibitors, inhibitors of
CDK4 (INK4) and kinase inhibitor proteins (KIPs), have
been reported to negatively modulate the activity of CDKs.
The latter include p21Cip1 [15], p27Kip1 [16], and p57Kip2
[17, 18]. It has been reported that overexpression of p21Cip1
leads to inhibited proliferation of mammalian cells and inac-
tivation of all cyclin-CDK complexes, indicating that it is a
universalcyclin-CDKinhibitor[19].p27Kip1,anegativeregu-
lator of protein kinases, interacts with cyclin E-CDK2 and
cyclin A-CDK2 which drive cells into the S phase of the
cell division cycle [20]. Moreover, p27Kip1 has been report-
edtoplayimportantrolesinG2/Mcheckpointastumorsup-
pressor [21].
In the present study, we focused on the mechanism
underlying anticancer eﬀects of 6-gingerol on colon cancer
with emphasis on cell viability alteration and cell cycle dis-
ruption. To investigate the alteration of cell viability and
cell cycle distribution induced by 6-gingerol, MTT assay and
ﬂow cytometric analysis were performed. Expression level
of important cell cycle regulators was determined by immu-
noblotting. Intracellular ROS was determined by using spec-
troﬂuorometrical analysis.
2.MaterialsandMethods
2.1. Materials. 6-gingerol, 2-propanol, 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 1-bu-
tanol, dimethyl sulfoxide (DMSO), 2 ,7 -dichloroﬂuorescein
diacetate (DCF-DA), deoxycholic acid, dithiothreitol, EDTA,
glycerol, Igepal CA-630, phenylmethylsulfonyl ﬂuoride
(PMSF), sodium chloride (NaCl), potassium chloride (KCl),
sodium dodecyl sulfate (SDS), sodium phosphate, Tris-HCl,
and trypsin/EDTA were purchased from Sigma (St. Louis,
MO, USA). Antibodies against cyclin A, cyclin B1, cyclin D1,
cyclin E, CDK1, p53, p21Cip1,p 2 7 Kip1,a n dβ-actin were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Peroxidase-conjugated antibodies against mouse IgG
orrabbitIgGwerepurchasedfromCellSignalingTechnology
(Beverly, MA, USA).
2.2. Cell Culture. Colon cancer cell line LoVo was obtained
from the American Type Culture Collection (ATCC; Rock-
ville, MD, USA) and maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% v/v fetal
bovine serum, 1% nonessential amino acid, 1% L-glutamine
(Gibco BRL, Gaithersburg, MD, USA), and 100μg/mL pen-
icillin/streptomycin (Sigma) at 37◦C in a humidiﬁed atmo-
sphere with 5% CO2. Cells were seeded in 10 cm Petri dish-
esataninitialdensityof2×105 cells/mLandgrowntoappro-
ximately 80% conﬂuence. Then, the cells were collected for
the subsequent analyses including cell viability, ﬂow cyto-
metric analysis, and immunoblotting analysis.
For 6-gingerol treatments, cells were starved for 24
hours (h) in serum-free DMEM and then incubated with 6-
gingerol at a series of concentrations in serum-free DMEM
(1, 5, 10, and 15μg/mL) for 24h or 48h.
2.3. Cell Viability Assay. Cell viability was determined by
MTT assay as previously described [20]. Brieﬂy, cells were
seeded at a density of 4 × 104 cells/well in a 24-well plate
andculturedwithserum-freeDMEMfor16h.Then,thecells
weretreatedwithserialconcentrationsof6-gingerol(0,5,10,
and 15μg/mL) for 24h or 48h. Treatment at each concentra-
tion was performed in triplicate. After treatments, the med-
iumwasaspiratedandcellswerewashedwithPBS.Cellswere
subsequently incubated with MTT solution (5mg/mL) for
4h. The supernatant was removed, and formazan was solu-
bilized in isopropanol and measured spectrophotometrically
at 563nm. The percentage of viable cells was estimated in
comparison with untreated cells.
2.4. Determination of Cell Cycle Distribution. Cell cycle dis-
tribution was analyzed by ﬂow cytometry. After 6-ginger-
ol treatment, cells were collected, ﬁxed with 1mL of ice-cold
70% ethanol, incubated at −20◦C for at least 24h, and cen-
trifugedat380 ×gfor5minatroomtemperature.Cellpellets
were treated with lmL of cold staining solution containing
20μg/mLpropidium iodide (PI),20μg/mLRNaseA,and1%
Triton X-100 and incubated for 15min in dark at room tem-
perature. Subsequently, the samples were analyzed in a FACS
Calibur system (version 2.0, BD Biosciences, Franklin Lakes,
NJ, USA) using Cell Quest software. Results were represent-
ative of at least three independent experiments.
2.5. Protein Extraction. After 6-gingerol treatments, cells
were trypsinized and homogenized in ice-cold lysis buﬀer
(50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.1% (v/v) Igepal
CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS,
1mM dithiothreitol, 0.1mM EDTA, and 1mM PMSF). After
sonication at 4◦C for 30min, the homogenate was cen-
trifuged at 14,000 ×g for 10min, and then the supernatant
was transferred into a new 1.5mL eppendorf and stored at
−70◦C for subsequent analysis. Protein concentration was
quantitated by the Bradford method (protein assay reagent;
Bio-Rad Laboratory, Hercules, CA, USA) according to the
manufacturer’s instruction.
2.6. Immunoblotting. Crude proteins (30μg of protein) were
subjectedtoa12.5%SDS-polyacrylamidegelandtransferred
ontoanitrocellulosemembraneaspreviouslydescribed[21].
The blot was subsequently incubated with 5% nonfat milk in
PBS for 1h, probed with a primary antibody against cyclin
A, cyclin B1, CDK1, p21Cip1,p 2 7 Kip1, p53, or β-actin for 2h
and then reacted with an appropriate peroxidase-conjugated
secondary antibody for 1h. All incubations were carried
o u ta t3 0 ◦C, and intensive PBS washing was performed
between incubations. After the ﬁnal PBS wash, the signal
was developed by ECL chemiluminescence, and the relative
photographic density was quantitated by image analysis
system (Fuji Film, Tokyo, Japan).Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: 6-Gingerol inhibited the cell viability of LoVo cells. Cells
were treated with indicated concentration of 6-gingerol for 24h or
48h, and the cell viability was analyzed by MTT assay. Data were
shown as the means ± SD. Three independent experiments were
performed for statistical analysis. ∗P<0.05 and ∗∗P<0.005 as
compared to control (C).
2.7. Determination of Intracellular Reactive Oxygen Species
(ROS). Production of ROS was determined by spectroﬂu-
orometrical method using 2 ,7 -dihydrodichloroﬂuorescein
diacetate (DCFH-DA) assay with modiﬁcation [22]. DCFH-
DA diﬀuses through the cell membrane and is enzymatically
hydrolyzed by intracellular esterases to the nonﬂuorescent
DCFH, which can be rapidly oxidized to the highly ﬂuores-
cent DCF, the ﬂuorescent product, in the presence of ROS.
After exposure to LPS and PFE, DCFH-DA was added to
the culture plates at a ﬁnal concentration of 5μM and incu-
bated for 40min at 37◦C in darkness. DCF ﬂuorescence
intensity was detected with emission wavelength at 530nm
andexcitationwavelengthat485nmusingaSpectraMaxPlus
microplate reader (Molecular Devices Corporation, Sunny-
vale,CA,USA).Thevalueswereexpressedasthemeanabsor-
bance normalized to the ratio of control value.
2.8. Statistical Analysis. Data were expressed as mean ± stan-
dard deviation (SD) of the three independent experiments.
Statistical signiﬁcance analysis was determined by using 1-
way ANOVA followed by Dunnett for multiple comparisons
with the control. The diﬀerences were considered signiﬁcant
for P values less than 0.05.
3. Results
3.1. 6-Gingerol Inhibited the Cell Viability of LoVo Cells. To
examine the inhibitory eﬀects of 6-gingerol on colon cancer
cells, LoVo cells were treated with a serial concentration of 6-
gingerol (1, 5, 10, and 15μg/mL) for 24 or 48h, respectively,
and then cell viability of LoVo cells was determined. As
shown in Figure 1, the cell viability in presence of 6-gingerol
was found decreased in association with the concentration
of 6-gingerol in a dose-dependent fashion. 6-Gingerol treat-
ments at concentrations of 10 and 15μg/mL signiﬁcantly
decreased cell viability to 68.7 ± 4.3% and 24.6 ± 2.1% of
controlfor24handto40.4 ± 1.4%and24.5 ± 1.4%ofcon-
trol for 48h, respectively (P<0.05 as compared to control).
3.2. 6-Gingerol Induced G2/M Phase Arrest but Not Apoptosis
in LoVo Cells. As a signiﬁcant suppression of cell viability of
LoVo occurred after 6-gingerol treatments resulted, cell cycle
distributionof6-gingerol-treatedLoVocellwasconsequently
analyzed and quantitated using ﬂow cytometry. As shown
in Figure 2, percentages of cells in sub-G1 phase, ranging
from 1.36 ± 0.23% to 2.58 ± 0.36%, were not signiﬁcantly
inﬂuenced by the treatments of 6-gingerol for 24h. However,
an increase in population of cells in G2/M phase after the
treatment was observed in a dose-dependent manner, rang-
ing from 45.7 ± 3.6% to 58.8 ± 5.4%, (5, 10 and 15μg/mL,
P<0.05).Additionally,anumberofG0/G1phasecells,rang-
ing from 43.8 ± 2.9% to 33.7 ± 3.2%, were signiﬁcantly
decreased with the concentration of 6-gingerol. The similar
change in population of G2/M phase and G0/G1 phase was
alsofoundinLoVocellstreatedwiththeserialconcentrations
of 6-gingerol for 48h. These results revealed that 6-gingerol
treatments increased the ratios of G2/M phase but decreased
G0/G1 phase of LoVo cells in a dose-dependent manner.
Moreover, 15μg/mL 6-gingerol treatment resulted in an
1.29-fold increase in number of cells in G2/M phase com-
pared with that after DMSO treatment. Amongst 4 phases
of cell cycle, G2/M phase arrest of LoVo cells was signi-
ﬁcant in response to 6-gingerol treatment.
As a slight change in percentage of sub-G1 phase of 6-
gingerol-treated LoVo cells was observed, a further experi-
ment was performed to investigate the involvement of apo-
ptosis in inhibited viability of LoVo cells upon exposure to
6-gingerol. Caspase 3, and 8 that are situated at pivotal junc-
tion in apoptosis pathway were monitored after 6-gingerol
treatment. No signiﬁcant change in the level of precursor
form and activated form of caspase 3 was observed in res-
ponse to 6-gingerol treatments (5, 10, and 15μg/mL) as well
as caspase 8 (Figure 3).
3.3. 6-Gingerol Diminished Levels of CDK1, Cyclin A, and
CyclinB1inLoVoCells. Havingobserved6-gingerol-induced
G2/Mphasearrest,theeﬀectsof6-gingeroltreatmentsoncell
cycle progress of LoVo cells were further investigated. Levels4 Evidence-Based Complementary and Alternative Medicine
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Figure 2:6-GingerolinducedG2/MphasearrestofLoVocells.Cells
were treated with indicated concentration of 6-gingerol for 24h or
48h,andthe percentages ofvarious cell cycle phases,including sub-
G1, G0/G1, S, and G2/M, were analyzed and quantitated by ﬂow
cytometry.Datawereshownasthemeans ±SD.Threeindependent
experiments were performed for statistical analysis. ∗P<0.05 and
∗∗P<0.005 as compared to corresponding control.
of important cell cycle mediators, including CDK1, cyclin
A, cyclin B1, cyclin D1, and cyclin E, were determined by
immunoblotting and relatively quantitated by densitometric
analysis. Our results showed that 6-gingerol treatments (5,
10, and 15μg/mL) dose-dependently decreased the levels of
CDK1, cyclin A, and cyclin B1 but slightly aﬀected the levels
of cyclin D1 and cyclin E (Figure 4). With the 6-gingerol
treatment at concentration of 15μg/mL for 24h, the levels
of CDK1, cyclin A, and cyclin B1 were reduced to 64%, 71%,
and 68% of control, respectively, by densitometric quanti-
tation (Figure 4).
3.4. 6-Gingerol Increased Levels of p21Cip1 and P27Kip1 in LoVo
Cells. Observing diminished levels of CDK1, cyclin A, and
cyclin B1 upon 6-gingerol treatments, we further investi-
gated the eﬀects of 6-gingerol treatments on cell cycle
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Figure 3: Eﬀects of 6-gingerol on activation of caspase 3 and cas-
pase 8 of LoVo cells. Cells were treated with indicated concentration
of6-gingerolfor24hor48h,andthenthecelllysatesweresubjected
to immunoblot for detection of caspase 3 and caspase 8. Protein
levels were relatively quantitated by densitometric analysis using
GAPDH as control.
regulators, p21Cip1 and p27Kip1. As shown in Figure 5,6 -
gingerol treatments (24h) dose-dependently increased levels
of p21Cip1 and p27Kip1 up to 1.65- and 1.46-fold, respectively,
compared to that of control. The trend of increase in p21Cip1
and p27Kip1 level was continuous in LoVo cells for further
24h. These ﬁndings revealed that 6-gingerol treatments
signiﬁcantly induced both of negative cell cycle regulators
p21Cip1 and p27Kip1.
3.5. 6-Gingerol Elevated p53 Level and Intracellular ROS in
LoVo Cells. Basing on that 6-gingerol treatment elevated
negative cell cycle regulator p21Cip1, the upstream regulator
of p21Cip1, p53 was further investigated. As shown in
Figure 6(a),6-gingeroltreatments(24h)elevatedlevelofp53
up to 1.89-fold as compared to that of control. The trend of
increase in p53 level was continuous in LoVo cells for further
24h. These ﬁndings revealed that 6-gingerol treatments sig-
niﬁcantly induced the important cell cycle regulator p53 in
LoVo cells.
ROS has been reported to play pivotal roles in phyto-
chemical-induced cell cycle arrest and apoptosis [23, 24].
Therefore, whether 6-gingerol induced ROS production in
LoVo cells was also analyzed. As shown in Figure 6(b),6 -
gingerol dose-dependently increased intracellular ROS up toEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀects of 6-gingerol on CDK1 and cyclins of LoVo cells. Cells were treated with indicated concentration of 6-gingerol for 24h or
48h, and then the cell lysates were subjected to immunoblot for detection of indicated proteins. Protein levels were relatively quantitated by
densitometric analysis using GAPDH as control.
p21Cip1
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Figure 5: Eﬀects of 6-gingerol on p21Cip1 and p27Kip1 of LoVo cells.
Cells were treated with indicated concentration of 6-gingerol for
2 4ho r4 8h ,a n dt h e nt h ec e l ll y s a t e sw e r es u b j e c t e dt oi m m u n o b l o t
for detection of p21Cip1 and p27Kip1. Protein levels were relatively
quantitated by densitometric analysis using GAPDH as control.
1.89-foldascomparedtothecontrol,andtheincreaseofROS
was diminished by NAC pretreatment. These results showed
that 6-gingerol signiﬁcantly increased level of p53 as well as
elevated intracellular ROS in LoVo cell.
4. Discussion
Previous studies have shown that treatment of 200μM6 -
gingerol induced G1 phase arrest and apoptosis in several
human colorectal cancer cells, including HCT-116, SW480,
HT-29, LoVo, and Caco-2 [25]. It is also reported that 6-gin-
gerol (60μM) shows a weaker eﬀect on induction of apop-
tosis of colorectal carcinoma COLO 205 than its analogue,
6-shogaol [26]. Similarly, our results demonstrate that a
relativelowconcentrationof6-gingerol(upto50μM)signif-
icantly suppresses the viability, induces G2/M phase arrest,
but does not provoke apoptosis of LoVo cells. Therefore, it
is suggested that low concentration of 6-gingerol tends to
inhibit growth of LoVo cells through induction of cell cycle
arrest instead of apoptosis.
Cyclin A2, an originally identiﬁed A-type cyclin, is ubi-
quitously expressed in mitotically dividing cells and is
upregulated in a variety of cancers [27, 28]. In late G1
phase, cyclin A binds to CDK2 to promote transition to S
phase and plays important roles in replication of DNA and
centromere in S phase [29]. Another type of cyclin is dis-
covered and coined as B-type cyclin of which the biological
role is not fully understood; however, the B-type cyclins
generally emerge during the G2-M phase transition of the
cell cycle. During G2-M phase transition, cyclin B1 binds
to CDK1 (cdc2) to form mitosis-promoting factor that
facilitates the transition from G2 to M phase of the cell
cycle [30]. Therefore, reduced levels of cyclin A and cyclin
B1 attenuate the activation of both CDK1 and CDK2, con-
sequently leading to the cell cycle arrest at S phase and G2/M
phase. In consistency with the phenomenon, our ﬂow cyto-
metric analysis showed a signiﬁcant increased percentage
of G2/M phase in 6-gingerol-treated LoVo cells (Figure 2),
suggesting that 6-gingerol may trigger the G2/M cell cycle
arrest via downregulation of cyclin A, CDK2, cyclin B1, and
CDK1.
Generally, the activity of cyclin-CDK complexes is reg-
ulated by two diﬀerent families of proteins known as INK4
and CDK inhibitors [31]. However, the tight regulation of
cell cycle progression is compromised in cancer cells, which
consequently results in aberrant proliferation of cells [32]. In
this regard, both INK4 and CDK inhibitor family members
have been reported to lose their functions in various
malignant cancers such as CRC, resulting in an uncontrolled
cell cycle progression and cancer growth [33, 34]. Therefore,
the molecular players such as cyclins, CDKs, and their inhi-
bitors serve as potential targets to halt the uncontrolled6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀects of 6-gingerol on p53 and intracellular ROS of
LoVo cells. (a) Cells were treated with indicated concentration of
6-gingerol for 24h or 48h, and then the cell lysates were subjected
to immunoblot for detection of p53. Protein levels were relatively
quantitated by densitometric analysis using GAPDH as control. (b)
Cells were treated with indicated concentration of 6-gingerol for
24h, and the intracellular ROS was determined as described in the
Section 2.
proliferation [35, 36]. Speciﬁcally, it could be argued that
the agents inducing the level and/or function of cell cycle
inhibitory regulators (INK4 and Cip/Kip family members)
might be useful in the control of various malignancies
including CRC. In the present study, our results clearly
showed an increase in the levels of p21Cip1 and p27Kip1 in
presence of 6-gingerol in LoVo cells, which is in line with the
observed G2/M phase arrest. Importantly, 6-gingerol caused
a dose- and time-dependent increase in the levels of p27Kip1
in LoVo cells, which supports the ﬁnding of cell cycle arrest
eﬀect in S or G2/M phase in this cell line.
6-gingerol has been reported to exert its anti-tumoral
activity via induction of ROS which is also known to trigger
activation of p53 and the consequent cell cycle arrest and
apoptosis [37].Ourresultsalsoshowed that6-gingerol signi-
ﬁcantly increased intracellular ROS as well as the critical cell
cycle regulator p53 in LoVo cells. These ﬁndings indicate that
6-gingerol increased p53 level may attribute to induction of
ROS. In conclusion, it could be suggested that 6-gingerol
induces ROS production and p53 activation as well as inhi-
bits the degradation of p27Kip1 and p21Cip1 in LoVo cells, by a
mechanism yet to be established, which induces the cell cycle
arrest at S and G2/M phases.
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